Between the two CCLs in our model system, we also observed a borderline significant higher expression of HNRNPA1 in the NEPC CCL NCI‐H660 compared to LNCaP (Figure S4 ).
← all excerpts
Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer.
1
—
—